Physician profile
Anne Maitland
NPI 1083660047
$291,951.45
in general payments reported to CMS, 2019-2025
31 companies · $20K in 2025
The $20K reported for 2025 was more than what 92% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $17K · 2021: $1,485 · 2022: $11K · 2023: $96K · 2024: $89K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $150K · Travel and Lodging: $42K · Food and Beverage: $7,101 · Consulting Fee: $6,378 · Education: $39.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $149,576.00 |
| Travel and Lodging | $41,877.97 |
| Food and Beverage | $7,101.19 |
| Consulting Fee | $6,378.00 |
| Education | $39.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $204,311.45 | 2022-2025 | Ayvakit |
| Genzyme Corporation | $34,613.30 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $29,615.04 | 2019-2024 | Dupixent |
| Genentech USA, INC. | $11,445.39 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $7,553.57 | 2019-2025 | |
| Csl Behring | $1,266.17 | 2019-2024 | Hizentra |
| Glaxosmithkline, LLC. | $477.89 | 2019-2025 | Nucala |
| Tersera Therapeutics LLC | $457.50 | 2023 | Quzyttir |
| Astrazeneca Pharmaceuticals Lp | $454.35 | 2019-2025 | Fasenra |
| Alk-Abello, INC | $348.42 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $310.59 | 2022-2025 | Orladeyo |
| Pharming Healthcare, INC. | $174.41 | 2023-2024 | Ruconest |
| Dermavant Sciences, INC. | $148.95 | 2023 | Vtama |
| Mauna Kea Technologies, INC. | $123.46 | 2024 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $79.04 | 2024-2025 | Xolair |
| Grifols USA, LLC | $57.32 | 2020-2024 | Gamunex-C, Xembify |
| Pfizer INC. | $54.98 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.77 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.47 | 2023 | Cinryze |
| Merck Sharp & Dohme LLC | $39.62 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $30.00 | 2023 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $26.50 | 2019-2020 | |
| Kaleo, INC. | $26.25 | 2019 | |
| Argenx US, INC. | $26.03 | 2024 | Vyvgart Hytrulo |
| Optinose US, INC. | $23.57 | 2020 | |
| Incyte Corporation | $22.16 | 2022 | |
| Shire North American Group INC | $22.13 | 2019 | |
| Octapharma USA, INC. | $21.90 | 2024 | Cutaquig |
| Abbvie INC. | $20.00 | 2024 | |
| Amgen INC. | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Maitland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.